Age-related macular degeneration is the leading cause of severe visual impairment in industrialized countries in patients
over 50 years of age. In its natural course, AMD leads to progressive loss of central vision, leaving the patients with only
orienting vision and the peripheral visual field at its final stage.
This chapter deals with the description of future trends in therapy. In fact, combination therapies will become more tailored
to the stage and severity of the disease. To provide long-term effects, long-acting delivery systems for drug combinations
need to be developed. In addition, combinations with surgical therapies, laser, or photodynamic treatment (PDT) might be reasonable
to decrease dosage and treatment intervals. For non-responders or advanced cases of AMD, cell-derived therapies will be necessary—like retinal transplantation or gene therapies— for better
restoration of a more normal foveal condition to restore the vision in an aging patient.
Keywords AMD – PTD – Therapy – human eye future directions – retinal transplantation